Poland· PL-100080020
Cloranxen
A potassium clorazepate product containing dikalii clorazepas, registered in Poland by Teva Pharmaceuticals Polska Sp. z o.o.. The same ATC class is registered in 7 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Potassium clorazepate is registered in 7 of 19 countries.
Countries holding a registration under ATC N05BA05 (potassium clorazepate), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Potassium clorazepate · ATC N05BA05
7 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of potassium clorazepate costs, country by country.
Normalised to the WHO defined daily dose (20 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Potassium clorazepate · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.83
The record
At a glance
URPL (Poland)- Active substance
- Dikalii clorazepas
- Manufacturer
- Teva Pharmaceuticals Polska Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- N05BA05
- ATC class
- Potassium clorazepate
- Defined daily dose
- 20 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990755912
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
192 interactions on record for potassium clorazepate.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Potassium clorazepate · interactions on record
192 records
- 4 severe
- 117 moderate
- 22 minor
Most severe, free to view
- MorphineN02AA01severe
- MorphinN07BC09severe
- HydrocodoneR05DA03severe
- CodeineR05DA04severe
49 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Potassium clorazepate in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a562d957-1eec-4e2b-a78d-dde91b9e571e GET /v1/drugs/a562d957-1eec-4e2b-a78d-dde91b9e571e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "10 mg",
"packaging": "05909990755912 ¦ Rp ¦ 44594\n30 tabl.",
"substance": "Dikalii clorazepas 10 mg",
"common_name": "Dikalii clorazepas",
"pl_product_id": "100080020",
"pozwolenie_nr": "07559",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about potassium clorazepate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.